A prospective cohort study providing insights for markers of adverse pregnancy outcome in older mothers by Lean, Samantha C. et al.
Lean et al. BMC Pregnancy Childbirth          (2021) 21:706  
https://doi.org/10.1186/s12884-021-04178-6
RESEARCH
A prospective cohort study providing 
insights for markers of adverse pregnancy 
outcome in older mothers
Samantha C. Lean1, Rebecca L. Jones1, Stephen A. Roberts2 and Alexander E. P. Heazell1* 
Abstract 
Background: Advanced maternal age (≥35 years) is associated with increased rates of adverse pregnancy outcome. 
Better understanding of underlying pathophysiological processes may improve identification of older mothers who 
are at greatest risk. This study aimed to investigate changes in oxidative stress and inflammation in older women and 
identify clinical and biochemical predictors of adverse pregnancy outcome in older women.
Methods: The Manchester Advanced Maternal Age Study (MAMAS) was a multicentre, observational, prospective 
cohort study of 528 mothers. Participants were divided into three age groups for comparison 20–30 years (n = 154), 
35–39 years (n = 222) and ≥ 40 years (n = 152). Demographic and medical data were collected along with maternal 
blood samples at 28 and 36 weeks’ gestation. Multivariable analysis was conducted to identify variables associated 
with adverse outcome, defined as one or more of: small for gestational age (< 10th centile), FGR (<5th centile), still-
birth, NICU admission, preterm birth < 37 weeks’ gestation or Apgar score < 7 at 5 min. Biomarkers of inflammation, 
oxidative stress and placental dysfunction were quantified in maternal serum. Univariate and multivariable logistic 
regression was used to identify associations with adverse fetal outcome.
Results: Maternal smoking was associated with adverse outcome irrespective of maternal age (Adjusted Odds Ratio 
(AOR) 4.22, 95% Confidence Interval (95%CI) 1.83, 9.75), whereas multiparity reduced the odds (AOR 0.54, 95% CI 0.33, 
0.89). In uncomplicated pregnancies in older women, lower circulating anti-inflammatory IL-10, IL-RA and increased 
antioxidant capacity (TAC) were seen. In older mothers with adverse outcome, TAC and oxidative stress markers 
were increased and levels of maternal circulating placental hormones (hPL, PlGF and sFlt-1) were reduced (p < 0.05). 
However, these biomarkers only had modest predictive accuracy, with the largest area under the receiver operator 
characteristic (AUROC) of 0.74 for placental growth factor followed by TAC (AUROC = 0.69).
Conclusions: This study identified alterations in circulating inflammatory and oxidative stress markers in older 
women with adverse outcome providing preliminary evidence of mechanistic links. Further, larger studies are 
required to determine if these markers can be developed into a predictive model of an individual older woman’s risk 
of adverse pregnancy outcome, enabling a reduction in stillbirth rates whilst minimising unnecessary intervention.
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Introduction
Advanced maternal age (≥35 years) is a growing trend 
in high income countries [1, 2]. Large epidemiological 
studies and subsequent meta-analysis have identified 
maternal age ≥ 35 years as an independent risk factor for 
adverse fetal outcomes including: fetal growth restriction 
(FGR), pre-term birth (PTB), pre-eclampsia (PE), neona-
tal intensive care unit (NICU) admission and stillbirth 
[3–8]. Stillbirths in older women are likely to occur near 
term with risks comparable to those in obesity, smok-
ing, diabetes or history of stillbirth [9–11]. However, 
unlike these conditions there are few guidelines to reduce 
adverse outcomes in older women [12, 13].
There is international recognition that older women 
should undergo additional antepartum screening or 
intervention to address the increased risk of stillbirth 
[14–17]. The RCOG and SOGC recommend offering 
induction of labour (IOL) at 39 weeks and/or additional 
monitoring from 38 weeks’ gestation [2, 15, 18]. Although 
not associated with an increase in the rate of Caesarean 
section [19], IOL may be viewed as an unnecessary inter-
vention as the majority of mothers will have uncompli-
cated pregnancies. Furthermore, induction may not be an 
acceptable intervention for older women without further 
indication, with poor recruitment (only 13.6%) of eligible 
women to the 35–39 trial consenting to be randomised 
[19]. Identification of mothers with highest risk would 
result in fewer interventions to prevent stillbirths.
Many pregnancy pathologies are associated with 
changes in oxidative stress and inflammatory status 
[20–22]. Similar changes are reported in aging pro-
cesses although these are usually researched in older 
populations [23, 24]. If these alterations were present in 
older women they could adversely affect placental func-
tion [25–27]. Previous work found evidence of placental 
dysfunction in pregnancies in older women including 
(but not limited to) reduced amino acid transport, aber-
rant cell turnover and reduced placental efficiency [28]. 
Therefore, it was hypothesised that the increased risk of 
adverse pregnancy outcome results from an aging mater-
nal environment and that a combination of biomarkers 
of aging, placental dysfunction, and clinical risk factors 
might identify women at greatest risk. This study aimed 
to determine whether there were changes in oxidative 
stress and inflammation in pregnancies in older mothers 
and whether changes in these biomarkers were evident in 
adverse pregnancy outcomes in this population.
Methods
Women were recruited to the Manchester Advanced 
Maternal Age Study (MAMAS) from March 2012–Octo-
ber 2014 from six UK maternity units after providing 
written informed consent. Ethical approval was obtained 
from the NRES Committee North West, (12/NW/0015). 
Pregnant women aged between 20 and 30 years (controls 
– optimal reproductive age), 35–39 years and ≥ 40 years 
were approached at 28 weeks’ gestation between April 
2012–June 2014. Women with multiple pregnancy, body 
mass index (BMI) < 18.5 or > 30 kg/m2, fetal abnormali-
ties, and pre-existing maternal medical conditions were 
excluded.
In addition to usual antenatal care, participants 
attended prenatal research appointments at 28 and 
36 weeks’ gestation (±1 week), at which detailed demo-
graphic, medical data and maternal blood samples for 
plasma and serum fractionation were collected. After 
delivery, outcome data were collected from medical 
records. Biochemical analyses were conducted after 
delivery, therefore not altering participants’ prenatal care.
The Index of Multiple Deprivation (IMD) – a measure 
of relative social deprivation [29] - was calculated from 
the mother’s address using NPEU-IMD tool (University 
of Oxford, UK). A composite adverse pregnancy out-
come was defined as one or more: small for gestational 
age (SGA) or FGR (< 10th/<5th centile respectively using 
individualised birthweight centiles (IBC) [30], still-
birth, admission to the NICU, PTB without infection 
(< 37 weeks gestation), and 5 min Apgar score < 7 in the 
absence of maternal diseases (diabetes/hypertension). 
Normal pregnancy outcome was defined as a term live 
birth (38–42 weeks), appropriately grown (IBC between 
10-95th centile) and absence of maternal or fetal compli-
cation (not limited just to those included in our defini-
tion of adverse pregnancy outcome). We conservatively 
estimated a 20% incidence of adverse pregnancy outcome 
(using data from Reference [8] stillbirth rate 0.4%, inci-
dence of FGR 6%, neonatal unit admission 8%, preterm 
birth 10%), therefore approximately 600 participants were 
required to obtain 120 women with composite adverse 
outcome; 120 women with adverse outcome would allow 
multivariable analysis of six covariates.
Nested case control studies
Two nested case-control studies were conducted i) to 
determine whether pregnancy in older mothers associ-
ated with elevated circulating biomarkers of inflamma-
tion and oxidative stress and ii) to determine whether 
adverse pregnancy outcome was associated with markers 
of aging and placental dysfunction in women ≥35 years 
of age. In the first nested case-control study samples 
from participants ≥40 years were matched (1:1) to 
mothers aged 20–30 and 35–39 years (n  = 40/group) 
for demographic (BMI, IMD, ethnicity (groups), mari-
tal status (married, single, partnership), smoking status 
(current/ex/non-smoker) and obstetric characteristics 
(normal vaginal delivery (NVD)). Women with adverse 
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pregnancy outcome, who conceived via assisted repro-
ductive technology (ART) or in whom maternal disease 
that developed post 28 weeks’ gestation were excluded. 
Sample sizes were determined following power calcula-
tions based on previous studies for detecting a difference 
in circulating oxidative stress [31–34] and inflammatory 
mediators [35–37]. For example, to detect a difference in 
cytokines TNF-α and IL-6 between normal and adverse 
outcomes in older women with 80% power with a 5% sig-
nificance level required between 28 and 43 participants 
in each group.
For the second nested case control study, cases were 43 
women ≥35 years of age who had an adverse outcome as 
defined above. Controls were participants with maternal 
age ≥ 35 years with a normal pregnancy outcome. Par-
ticipants that had maternal disease that developed post 
28 weeks, PTB associated with infection, or incomplete 
outcome data were excluded. Groups were matched for 
demographic characteristics (maternal/paternal age, eth-
nicity, BMI, smoking status, marital and housing (owner-
ship/rental) status and parity (primi/multiparous.
Biomarkers of aging were measured in maternal serum 
or plasma samples for participants included in the nested 
case control studies (Supplementary Table  1). Absorb-
ances were measured using a microplate reader (FLU-
OStarOmega, BMG Labtech) for all Enzyme linked 
immunosorbent assays (ELISAs). Pro/anti-inflammatory 
cytokines (interleukin (IL)-1α, IL-1β, IL-1Ra, IL-6, IL-10 
and tumour necrosis factor (TNF)-α) were quantified in 
maternal serum using DuoSet®ELISAs (R&D Systems, 
Abingdon, UK) following an optimised protocol [27].
Maternal plasma antioxidant concentration was quan-
tified using OxiSelect™ Total Antioxidant Capacity 
Assay Kit (Cell Biolabs, Inc., San Diego, USA). Oxida-
tive damage markers 8-Isoprostane and DNA/RNA oxi-
dative damage were measured by EIA Kits and Protein 
Carbonyl Calorimetric Assay Kit (Cayman Chemical 
Company, Michigan, USA). Maternal serum placental 
hormones (hCG, PAPP-A, Progesterone and hPL were 
quantified using DRG ELISA kits (DRG Instruments, 
Marburg, Germany). Placental growth factor (PlGF) and 
soluble fms-like tyrosine kinase-1 (sFlt) were quantified 
using DuoSet® ELISAs (R&D systems). All assays were 
conducted according to the manufacturer’s standard 
protocols.
Statistical analysis
Demographic data were compared using Fisher’s Exact 
test for categorical data and Kruskal-Wallis tests with 
Dunn’s multiple comparisons or Mann Whitney U tests 
for continuous data. Univariate logistic regression was 
conducted on the whole dataset to identify demographic 
or clinical variables associated with composite adverse 
pregnancy outcome. Multivariable logistic regression was 
used to quantify the effect of maternal age on adverse 
outcome; in this analysis maternal ethnicity, use of ART, 
smoking status, parity, IMD and home ownership were 
included as categorical variables and in an second model, 
paternal age was included as an additional categorical 
variable (< 30, 30–34, 35–39 and 40+ years). The logistic 
regression analyses were conducted using STATA (Ver-
sion 14, StataCorp, Texas, USA). Biomarker analysis was 
performed on GraphPad Prism (Version 6.04, GraphPad 
Software Inc., La Jolla, USA) using Kruskal-Wallis with 
Dunn’s multiple comparisons tests on untransformed 
data or Mann-Whitney U where appropriate. Due to 
wide dispersion in the cytokine data, including values 
at the lower limit of detection of the assay, these data 
were transformed as log(y + smallest detectable value) 
for analysis. Gestational age effects were assessed using 
Spearman’s correlation. Markers that showed statisti-
cal significance at the p < 0.01 level were analysed to test 
their predictive potential as markers of adverse preg-
nancy outcome in women aged ≥35 years by calculation 
of the area under the receiver operator characteristic 
curve (AUROC).
Results
Overall, 1134 women were approached to participate in 
MAMAS. 571 of these mothers (51%) either did not meet 
the inclusion criteria or declined to participate (Fig.  1). 
563 mothers consented before 28 weeks’ gestation. A fur-
ther 45 participants were recruited between 28 weeks’ 
gestation and birth. 80 mothers (14%) were either lost to 
follow up or withdrew from the study between 28 weeks’ 
gestation and birth. Therefore, demographic, medi-
cal and pregnancy data was collected on a final cohort 
of 528 participants (n = 154 20–30, n = 222 35–39 and 
n = 152 ≥ 40 year olds).
There were no differences between ethnicity, employ-
ment and deprivation between participants in differ-
ent age groups (Table  1). Paternal age was higher in 
pregnancies to women aged 35–39 and ≥ 40 years, and 
women in both these groups had higher BMI compared 
to 20–30 year olds. More mothers aged 35–39 years were 
married, and more mothers aged 20–30 years were in 
partnerships than the other maternal age groups. More 
older mothers were non-smokers, homeowners, multipa-
rous and had previous or current fertility treatment (pre-
dominantly in  vitro fertilisation) compared to women 
aged 20–30. Of those who conceived using assisted 
reproductive technologies, 45% of those ≥40 years used 
egg and/or sperm donors, compared to 5% of 35–39 year 
olds.
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Fig. 1 Flow diagram of participant recruitment and retention in the MAMAS cohort study
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Table 1 Demographic data for total MAMAS participants
Data are mean (range) or percentage (number). BMI Body mass index, CP Civil partnership, IMD Index of multiple deprivation, APO Adverse pregnancy outcome, ART 
Assisted reproductive therapies, IVF In vitro fertilisation, Donor = egg and/or sperm, IUI Intrauterine insemination. Statistical differences are aKruskal-Wallis with Dunn’s 
multiple comparisons or b Fishers exact test. c expressed as percentage of parous women. When overall p > 0.05, multiple comparisons p values are reported († 20–30 
vs. 35–39 years, ¶ 20–30 vs ≥40 years, Δ 35–39 vs. ≥40 years). Significant differences are highlighted with bold p values
Demographics 20–30 Years (n = 154) 35–39 Years (n = 222) ≥40 Years (n = 152) P value Overall P value Multiple Comparisons
Maternal age 26 (20–30) 37 (35–39) 42 (40–49)
Paternal Age a 29 (18–48) 38 (21–50) 43 (24–60) < 0.001 †¶Δ < 0.0001
BMI (kg/m2) a 23.8 (18.7–29.9) 24.1 (18.5–29.5) 24.9 (19.0–29.9)
1 missing value
0.0026 †0.10, ¶0.0004, Δ0.008
European  Ethnicityb 90% (138) 87% (191) 95% (144) 0.08
Marital Status b
 Single 5% (7) 2% (5) 5% (8) 0.001 †< 0.001, ¶0.15, Δ0.08
 Married/CP 45% (69) 66% (146) 55% (83)
 Partner 51% (78) 31% (69) 39% (60)
 Other 0% (0) 1% (1) 1% (1)
Occupation b
 Employed – Full Time 55% (84) 49% (109) 59% (89) 0.51
 Employed – Part Time 26% (40) 32% (72) 26% (40)
 Unemployed 18% (28) 16% (35) 14% (21)
 Unknown 1% (2) 3% (6) 1% (2)
Smoking Status b
 Non-smoker 71% (110) 74% (165) 81% (123) 0.056
 Current 11% (17) 5% (12) 3% (5)
 Ex-smoker 18% (27) 20% (45) 16% (24)
Housing b
 Owns 45% (70) 73% (163) 84% (127) < 0.001 †¶ p < 0.001,Δ0.023








 Primiparous 49% (76) 28% (62) 34% (52) < 0.001 † < 0.001, 0.001, Δ0.092
 Parous 51% (86) 72% (160) 66% (100)
Previous APO b,c 22% (17) 32% (51) 22% (22) 0.12
 FGR c 13% (10) 21% (33) 11% (11) 0.09
 Stillbirth c 0% (0) 3% (4) 4% (1) 0.52
Previous ART b < 1% (1) 8% (18) 18% (28) < 0.001 †0.001, ¶ < 0.001, Δ0.004
ART b < 1% (1) 9% (21) 14% (22) 0.004 †0.001, ¶ < 0.001, Δ0.005
 Hormonal < 1% (1) 2% (5) 1% (2)
 IVF 0% (0) 6% (13) 7% (10)
 IVF - Donor 0% (0) < 1%(1) 7% (10)
 IUI 0% (0) 1% (2) 0% (0)
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Older women delivered moderately earlier than women 
aged 20–30 years (39 weeks + 3 days vs. 40 weeks + 2 days; 
Table 2). Women ≥40 years had a 43% rate of IOL com-
pared to 26–32% in the younger groups (p  = 0.002). 
Fewer older mothers had NVDs (39% vs 50 and 60%) 
p = 0.001) and more had elective or emergency caesar-
ean sections. Birthweight, IBC and the incidence of preg-
nancy-related maternal disease did not differ between 
the maternal age groups. Four women in MAMAS had 
a stillbirths (between  38+ 1 and  40+ 3 weeks gestation), all 
were ≥ 40 years old (p = 0.007).
Demographic predictors of adverse pregnancy out-
come: Univariate logistic regression demonstrated that 
ex- and current smokers had higher odds of adverse 
pregnancy outcome than non-smokers (OR 1.96 
(95%CI 1.17–3.30) and 3.97 (95%CI 1.92–8.21), p = 0.01 
and < 0.001 respectively; Table 3). Multiparity was protec-
tive against adverse pregnancy outcome (OR 0.67 (95%CI 
0.44–1.03), p = 0.05) compared to primiparous women. 
In this population, maternal ethnicity did not indepen-
dently affect the risk of adverse pregnancy outcome. ART 
had no detectable effect on outcome (OR 0.94 (95%CI 
0.44–2.01) p = 0.88). Paternal age had a protective effect 
against adverse outcome (OR 0.54 (95%CI 0.31–0.94) 
p = − 0.03). Only the associations between adverse preg-
nancy outcome and maternal parity or cigarette smok-
ing remained statistically significant after adjusting for 
maternal ethnicity, parity, smoking status, housing, and 
paternal age (Table  3). Following adjustment for covari-
ates maternal age ≥ 40 was associated with increased risk 
of adverse perinatal outcome (AOR 2.67, 95% CI 1.09–
6.52, p = 0.03).
Table 2 Pregnancy outcome of MAMAS participants
Data are mean (range) or percentage (number). Statistical differences are aKruskal-Wallis with Dunn’s multiple comparisons or b Fishers exact test. c Expressed 
as proportion of babies born alive. When overall p > 0.05, multiple comparisons p values are reported († 20–30 vs. 35–39 years, ¶ 20–30 vs ≥40 years, Δ 35–39 vs. 
≥40 years)
Pregnancy Outcome 20–30 Years (n = 154) 35–39 Years (n = 222) ≥40 Years (n = 152) P value Overall P Value Multiple 
Comparisons
Gestation at Delivery a 40 + 2 39 + 4 39 + 3 < 0.001 †0.003, ¶ < 0.0001, Δ0.04
Weeks + days (34 + 1–42 + 5) (39 + 6–43 + 1) (30 + 5–42 + 4)
Birthweight (g) a 3416 (1880–4680) 3438 (1300–4900) 3375 (1480–4420) 0.94 –
Individualised Birthweight 
Centile a
38.4 (0.1–98.7) 45.3 (0.0–99.6) 47.7 (0.0–99.4) 0.35 –
Induction of Labour b 32% (50) 26% (58) 43% (66) 0.002 †0.20, ¶0.06, Δ 0.001
Mode of Birth b
 Normal Vaginal Delivery 60% (102) 50% (117) 39% (64) < 0.001 † 0.001,¶ < 0.001, Δ 0.17
 Elective Caesarean Section 13% (12) 25% (47) 25% (35)
 Emergency Caesarean 
Section
8% (12) 10% (25) 17% (26)
 Instrumental Vaginal 
Delivery
19% (28) 15% (33) 19% (27)
Maternal Disease b
 Preeclampsia 5% (8) 1% (2) 3% (4) 0.04 † 0.01,¶ 0.38, Δ 0.23
 Gestational Diabetes 
Mellitus
1% (2) 3% (7) 3% (4) 0.56
NPO b 77% (119) 81% (180) 80% (121) 0.67
APO b 23% (35) 19% (42) 20% (31) 0.69
Components of APO
 Pre-Term Birth 6% (9) 6% (13) 6% (9) 1.00
 Small for gestational Age 10% (15) 11% (25) 9% (14) 0.73
 Fetal Growth Restriction 3% (5) 7% (16) 4% (6) 0.21
 Large for Gestational Age 3% (4) 5% (12) 4% (6) 0.40
 Neonatal Unit Admission c 4% (6) 7% (15) 7% (11) 0.36
 Stillbirth 0% (0) 0% (0) 3% (4) 0.007 †1.00, ¶0.06, Δ 0.03
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Table 3 Unadjusted and adjusted odds ratios for prediction of adverse pregnancy outcome of MAMAS participants
Model 1 – multivariable logistic regression including all variables except paternal age (ethnicity, parity, smoking, house ownership, IMD quintile and maternal age 
group), Model 2 – multivariable regression additionally adjusting for paternal age. ART Assistive Reproductive Techniques, IMD Index of multiple deprivation, IMD 
Quintile 1st = least deprived, 5th = most deprived. Statistics performed were univariate and multivariable meta-regression. Adjustments included maternal ethnicity, 





Unadjusted Model 1 Model 2
OR (95% CI) P value AOR (95% CI) P value AOR P value
Ethnicity
 European 373 (89) 101 (94) Reference Reference Reference
 Asian 24 (6) 5 (5) 0.77 (0.29–2.07) 0.49 0.73 (0.25–2.13) 0.57 0.58 (0.18–1.88) 0.37
 Other 23 (5) 2 (2) 0.32 (0.74–1.38) 0.08 0.27 (0.06–1.28) 0.081 0.27 (0.54–1.32) 0.11
Parity
 Nulliparous 143 (34) 47 (44) Reference Reference Reference
 Multiparous 277 (66) 61 (56) 0.67 (0.44–1.03) 0.07 0.58 (0.36–0.93) 0.03 0.56 (0.33–0.89) 0.02
ART 
 None 383 (91) 99 (92) Reference Reference Reference
 ART 37 (9) 9 (8) 0.94 (0.44–2.01) 0.88 1.01 (0.44–2.29) 0.99 0.85 (0.35–2.04) 0.71
Smoking
 No 332 (79) 66 (61) Reference Reference Reference
 Ex 69 (16) 27 (25) 1.96 (1.17–3.30) 0.01 1.86 (1.08–3.24) 0.03 1.85 (1.05–3.25) 0.03
 Current 19 (5) 15 (14) 3.97 (1.92–8.21) < 0.001 4.24 (1.88–9.54) < 0.001 4.22 (1.83–9.75) 0.001
Housing
 Rented 123 (29) 45 (42) Reference Reference Reference
 Owns 297 (71) 63 (58) 0.58 (0.37–0.90) 0.01 0.57 (0.34–0.97) 0.04 0.56 (0.32–0.98) 0.04
IMD Quintile
 1st 73 (18) 19 (18) Reference Reference Reference
 2nd 78 (20) 29 (27) 1.42 (0.74–2.74) 0.29 1.31 (0.66–2.60) 0.53 1.37 (0.68–2.76) 0.38
 3rd 97 (24) 13 (12) 0.51 (0.24–1.11) 0.09 0.46 (0.21–101) 0.05 0.48 (0.21–1.10) 0.08
 4th 68 (17) 21 (20) 1.19 (0.59–2.40) 0.63 0.92 (0.44–1.93) 0.82 0.98 (0.46–2.10) 0.97
 5th 82 (21) 22 missing 
values
14 (23) 2 missing 
values
1.12 (0.57–2.22) 0.74 0.98 (0.46–2.08) 0.96 1.02 (0.48–2.23) 0.94
Paternal Age
 < 30 years 86 (21) 33 (32) Reference Reference
 30–34 years 58 (14) 16 (15) 0.77 (0.39–1.51) 0.45 0.86 0.72
 35–39 years 115 (28) 24 (23) 0.54 (0.30–0.98) 0.04 0.54 0.16




0.54 (0.31–0.94) 0.03 0.46 0.08
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Fig. 2 Circulating inflammatory markers in women grouped by maternal age, n = 40/group. Maternal serum at 28 weeks (A, C, E, G, I) and 
36 weeks (B, D, F, H, J) gestation concentrations of: A, B interleukin (IL-1) α, C, D IL-1β, E, F IL-1Ra, G, H IL-10 and (I-J) TNFα. Data are logarithmically 
transformed, with median, interquartile range (box) and total range (whiskers) plotted. Analysed using one-way ANOVA (*p < 0.05, **p < 0.01)
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Nested case‑control study to determine whether advanced 
maternal age associated with elevated circulating 
biomarkers of inflammation and oxidative stress
The characteristics of participants (n = 40/group) in this 
nested study are shown in Supplementary Table  2. The 
three groups differed for factors strongly associated with 
older age: higher home-ownership in 35–39 and ≥ 40 year 
olds (95% of ≥40 vs. 90% of 35–39 vs. 58% of 20–30 years) 
and multiparous (78% of ≥40 vs. 80% of 35–39 vs. 53% 
of 20–30 yeas) and mothers ≥40 years had higher previ-
ous miscarriage rates (53% vs. 25% of 20–30 years). Older 
mothers gave birth earlier (by 5–7 days) than 20–30 year 
olds (p < 0.001; Supplementary Table 3).
Large variation was seen in inflammatory biomarker 
concentrations in maternal serum. At 28 weeks’ ges-
tation, lower circulating concentrations of IL-1α and 
IL-1RA (p  = 0.04 and 0.005, Fig.  2A, E) were meas-
ured in mothers 35–39 years compared to 20–30 years, 
but no significant differences were present between 
20 and 30 and ≥ 40 year olds. Similar trends were 
apparent at 36 weeks gestation but were not statisti-
cally significant. Anti-inflammatory IL-10 was lower 
in mothers ≥40 years at 28 weeks’ (p  = 0.05), with a 
stepwise age-related decrease apparent at 36 weeks 
(p  = 0.03, Figs.  2G-H). No differences were seen in 
IL-1β or TNF-α at 28 weeks or 36 weeks between age 
groups (Fig.  2). There were no differences in maternal 
circulating markers of oxidative stress at 28 weeks’ ges-
tation (Fig.  3A, C, E). TAC was increased at 36 weeks’ 
gestation in mothers ≥40 years compared to controls 
(p = 0.015; Fig.  3B). No differences of other oxidative 
stress markers were seen (Fig.  3D and F, Supplemen-
tary Figure 1). Gestational age affected TAC in mothers 
≥40s (p = 0.004), whereas 8-isoprostane was positively 
related to gestational age in all groups (p < 0.001; data 
not shown). When assessing change in oxidative sta-
tus over time, TAC levels fell across the third trimester 
in controls but increased in older women (p = 0.005; 
Fig.  3G). In contrast, elevated lipid peroxidation 
(8-isoprostane) was apparent in mothers 20–30 and 
35–39 years across the third trimester but decreased 
in women ≥40 (p = 0.04; Fig.  3H). There was a posi-
tive relationship between TAC and 8-isoprostane in all 
participants at 28 weeks’ gestation, strongest in women 
35–39 years (r  = 0.61 vs 0.45 in women aged 20–30, 
Fig.  3I). At 36 weeks a negative correlation existed 
between TAC and 8-isoprostane in women 35–39 
and ≥ 40 years (r  = − 0.42 and − 0.39 respectively; 
p = 0.005 and p = 0.01 Fig. 3J), whereas no relationship 
was seen in women aged 20–30 (r = − 0.17, p = 0.32).
Nested case‑control study to determine whether maternal 
biomarkers associated with adverse pregnancy outcome 
in older women
Women ≥35 years of age who had an adverse pregnancy 
outcome (n  = 43) were well matched for demographic 
variables to women ≥35 years of age who had a normal 
pregnancy outcome (Supplementary Table 4). The major-
ity of infants in the group of women with adverse preg-
nancy outcome were classified as SGA (84%), with 44% 
under the 5th centile (FGR) (Supplementary Table  5). 
There were fewer NVDs (39% vs. 65%, p  = 0.02) and 
more EMCS (23% vs. 7%, p  = 0.04) in the group with 
adverse pregnancy outcomes compared to those with 
a normal outcome. A quarter of mothers in the adverse 
pregnancy outcome group delivered preterm (< 37 weeks, 
p  < 0.001) and a quarter of infants were admitted to 
NICU (p < 0.001). There were three stillbirths included in 
the adverse pregnancy outcome group (one stillbirth was 
excluded due to congenital abnormality identified as the 
cause of death).
There were no differences in circulating cytokines at 
28 weeks’ or 36 weeks’ gestation between older women 
with normal and adverse pregnancy outcome (Supple-
mentary Figure 2). TAC was higher in older mothers with 
adverse pregnancy outcome compared to normal out-
comes at both 28 and 36 weeks’ gestation (p = 0.002 and 
0.006 respectively, Fig.  4A, B). 8-isoprostane increased 
between 28 and 36 weeks’ gestation in both normal and 
adverse pregnancy outcome groups (data not shown). 
8-isoprostane also significantly increased in older moth-
ers with adverse pregnancy outcome at 28 weeks but 
was not elevated at 36 weeks’ gestation (p  = 0.01 and 
p  = 0.82 respectively, Fig.  4E-F). No differences were 
detected in markers of DNA/RNA damage or protein 
carbonyl between groups at either 28 weeks (p  = 0.66 
and 0.34 respectively) or 36 weeks’ gestation (p  = 0.57 
and 0.60 respectively; Fig.  4C, D, G, H). A positive cor-
relation between TAC and 8-isoprostane at 28 (r = 0.46 
for adverse pregnancy outcome and 0.31 for normal 
Fig. 3 Levels of markers of oxidative stress status in women grouped by maternal age; n = 40/group. Maternal serum at 28 weeks (A, C, E) and 
36 weeks (B, D, F) gestation was quantified for: A, B Total Antioxidant Capacity (TAC), C, D 8-Isoprostane and E, F protein Carbonyl. Rate of change 
between 28 and 36 weeks’ gestation of: G Total Antioxidant Capacity (TAC) and H 8-Isoprostane. Data presented as median, interquartile range 
(box) and total range (whiskers). Analysed using Kruskal-Wallis with Dunn’s multiple comparisons or one-way ANOVA on transformed data. TAC was 
correlated with log 8-isoprostane at I 28 weeks and J 36 weeks using Spearman rank test (*p < 0.05, **p < 0.01), *** p < 0.001)
(See figure on next page.)
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pregnancy outcome) and at 36 weeks with normal out-
comes (r = − 0.39; p = 0.01 Fig. 4J), whereas there was no 
relationship seen in women with adverse pregnancy out-
come (r = − 0.33, p = 0.07, Fig. 4I-J).
Concentrations of hPL, PlGF and PlGF:sFlt ratio were 
unchanged at 28 weeks’ gestation (Fig.  5A, C, G). hPL 
was lower at 36 weeks’ gestation in women with adverse 
pregnancy outcome (p = 0.007; Fig.  5B). Similarly, PlGF 
concentrations were lower at 36 weeks’ when measured 
alone (p  < 0.001, Fig.  5D) or adjusted for sFlt-1 (human 
VEGF R1/Flt-1) concentrations (p  = 0.03, Fig.  5H). 
sFlt-1 was lower in women with adverse pregnancy out-
come at 28 weeks’ with a similar trend at 36 weeks’ ges-
tation (p = 0.05 and 0.07, Fig. 5E,F). No differences were 
detected in circulating hCG, PAPP-A or progesterone 
with adverse pregnancy outcome (Supplementary Fig-
ure 3). ROC curves were created for all biomarkers that 
reached a statistical significance of p < 0.01 between nor-
mal pregnancies and those with adverse pregnancy out-
come. TAC and 8-isoprostane had predictive area under 
the curve values of 0.69 and 0.66 respectively (ranked as 
a poor prognostic markers, Fig.  6A-B), whilst hPL and 
PlGF had predictive values of 0.68 (poor) and 0.74 (fair), 
respectively (Fig. 6C-D).
Discussion
This prospective study found that increased maternal age 
was associated with increased total antioxidant capacity 
and a reduction in anti-inflammatory IL-10 and IL-RA 
indicating changes in oxidative stress and inflammation 
over the timeframe of reproductive life span. In mothers 
≥35 years of age, adverse pregnancy outcome was associ-
ated with a further increase in total antioxidant capacity 
and a reduction in placentally-derived biomarkers, hPL 
and PlGF. In this population, maternal smoking and pri-
miparity were independent risk factors for adverse out-
come, consistent with retrospective study findings [7, 10, 
38].
Strengths and limitations
This prospective study was designed to explore poten-
tial mechanisms underpinning the association between 
advanced maternal age and adverse pregnancy outcome, 
to identify potential biomarkers and generate further 
hypotheses which can be explored. The multi-centre 
approach used in this study offered diversity, making it 
more representative of the UK maternity population. 
However, this study would have benefitted from larger 
overall sample size to increase the statistical power to 
confirm associations between adverse pregnancy out-
come and biomarkers and assess the predictive ability 
of combinations of clinical and biochemical markers. 
Furthermore, a larger cohort would have enabled larger 
nested case control studies, with greater statistical power, 
particularly for cytokine biomarkers which had wide 
variation in levels between individuals. In addition, the 
study excluded women with a BMI above 30, which may 
account for some of the increased adverse outcomes 
observed in older women (as older women have a higher 
BMI than younger women). We recognize this limitation 
of the study and believe that BMI is an important covari-
ate to include in future studies to determine the degree of 
interaction between these two variables that are indepen-
dently associated with adverse pregnancy outcome.
Despite these limitations, MAMAS is a large prospec-
tive study investigating associated factors for adverse 
pregnancy outcome in older women and our detailed 
data collection provided the ability to adjust for multiple 
confounding variables, and delineate the effects of pater-
nal age, ethnicity and parity and socioeconomic status, all 
of which may be associated with stillbirth [39–42].
Interpretation
Consistent with other larger retrospective studies the 
clinical factors associated with adverse outcome in 
older women were maternal smoking and primiparity 
[8, 10, 38]. However, in our study population concep-
tion by ART had no significant association with stillbirth, 
although the effect-size of other studies was within the 
95% confidence intervals of our population [43, 44]. It 
is notable that in this and other studies, older mothers 
were more likely to own their own homes, be in a stable 
relationship, have higher rates of education and had the 
lowest rates of cigarette smoking [45], factors which are 
associated with lower risk of adverse outcomes such as 
stillbirth and fetal growth restriction [46]. However, the 
opposite finding that older women have higher rates of 
these conditions is noted in observational studies [8]. 
These findings suggest that other mechanisms much 
account for the increased rate of adverse maternal and 
(See figure on next page.)
Fig. 4 Levels of oxidative stress markers maternal serum from women ≥ 40 years of age with normal and adverse pregnancy outcome; n = 43/
group. Maternal serum at 28 weeks (A, C, E, G) and 36 weeks (B, D, F, H) gestation against pregnancy outcome. A, B Total Antioxidant Capacity (TAC), 
C, D DNA/RNA damage, E, F 8-Isoprostane and G, H Protein Carbonyl. Data are (A, B) median, IQR and range, Mann Whitney test or (C-H) unpaired 
t-test for transformed data. TAC was correlated with 8-isoprostane at (G) 28 weeks and (H) 36 weeks gestation using Spearman rank test (*p < 0.05, 
**p < 0.01)
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neonatal outcomes in older mothers. Furthermore, they 
also emphasise the need to promote smoking cessation 
services and suggest that women who have their first 
pregnancy over the age of 35 or those who smoke should 
be prioritised for intervention.
Understanding the mechanisms underlying the suscep-
tibility to adverse outcomes is essential to improve identi-
fication of older women highest risk of adverse outcomes. 
This study focussed on processes implicated in maternal 
aging and placental dysfunction. A pro-inflammatory 
bias and elevated oxidative stress are established hall-
marks of aging [47–49] and both are strongly associated 
with pregnancy pathologies, particularly those character-
ised by placental dysfunction [50–52]. The nested case 
control studies revealed features of biological aging in 
older women in the absence of adverse outcome includ-
ing: elevations in TAC, coincident with reduced oxidative 
damage (reduced lipid peroxidation) and a reduction in 
anti-inflammatory cytokines (IL-10 and IL-1Ra) possi-
bly indicating a shift towards a pro-inflammatory state. 
The former findings are consistent with these women 
delivering healthy infants and suggest that adaptive 
antioxidant responses are effective in maintaining the 
oxidant:antioxidant balance protecting against oxidative 
stress [53]. The reduction in IL-10 levels has also been 
seen in serum and placenta of women perceiving reduced 
fetal movements [27] and in the placenta of infants with 
FGR [54]. As both FGR and RFM are associated with pla-
cental dysfunction, the reduction in IL-10 could be con-
sistent with the increased placental dysfunction seen in 
older mothers [28]. Critically, an isolated reduction in 
anti-inflammatory status is not detrimental, but studies 
of the IL-10 knockout mouse demonstrate increased sus-
ceptibility to inflammatory stimuli resulting in PTB and 
fetal loss [55], and exacerbation of the vascular symp-
toms of preeclampsia [56] and effects of hypoxia [57]. 
Therefore, an age-related decline in anti-inflammatory 
cytokines may increase vulnerability of older women 
to inflammation and the associated detrimental effects 
observed on placental function and should therefore be 
further explored [58]. We speculate that maternal aging 
creates a suboptimal environment for placental and fetal 
development that contributes to the vulnerability to 
adverse outcomes.
In this population adverse pregnancy outcome was 
associated with higher circulating levels of 8-isoprostane 
at 28 weeks’ gestation, indicating elevated oxidative dam-
age, despite higher antioxidant capacity. Inadequate 
antioxidant compensatory responses resulting in oxida-
tive stress has been detected in placentas from adverse 
pregnancy outcome, where it has been related to altered 
placental function [22]. Future studies are required to 
confirm whether placental oxidative damage is impli-
cated in the placental dysfunction observed in pregnan-
cies in older mothers.
Consistent with other reports reduced maternal circu-
lating concentrations of placental hormones (hPL, sFlt 
and PlGF) were detected in pregnancies in older women 
with adverse outcome compared to normal outcomes. 
The differences in placental hormones provide further 
evidence for placental dysfunction as an underpinning 
mechanism for susceptibility to adverse outcomes in 
older women. There is a growing body of evidence that 
these represent biomarkers of placental dysfunction, and 
are lower in pregnancies with FGR, PE and stillbirth [59–
61]. PlGF and sFlt concentrations in the maternal circu-
lation are correlated with fetal size as early as the first 
trimester [62] and have strong potential as biomarkers for 
adverse pregnancy outcome in a clinical setting [61, 63]. 
In common with prognostic accuracy studies from other 
contexts in pregnancy, PlGF had the strongest predictive 
value for adverse pregnancy outcome in older mothers 
[64], although the AUROC is insufficient for clinical util-
ity at present. Further studies with larger sample size are 
required to determine if a prognostic model incorporat-
ing the clinical and biochemical predictors with sufficient 
predictive power to identify older women at greatest risk 
of adverse outcome can be derived.
Conclusion
This study has identified alterations in circulating bio-
markers of inflammation and oxidative stress markers in 
older pregnant women, suggesting that biological pro-
cesses seen in aging may contribute to susceptibility to 
adverse outcomes in this population. Furthermore, we 
identified serum biomarkers with fair predictive accu-
racy for adverse pregnancy outcome in older women. 
With larger sample sizes and data sets, and by combining 
identified demographic and clinical variables that alter 
risk of adverse outcome and the measurement of aging 
and placental biomarkers, it may be possible to create a 
Fig. 5 Levels of placental hormones in maternal serum from women ≥ 40 years of age with normal and adverse pregnancy outcome (n = 43/
group). Maternal serum/plasma at 28 weeks (A, C, E, G) and 36 weeks (B, D, F, H) gestation against pregnancy outcome. A, B human placental 
lactogen (hPL), C, D Placental growth factor (PlGF), E, F Soluble fms like tyrosine kinase-1 (sFlt) and G, H PlFG:sFlt ratio. Data presented as median, 
interquartile range (box) and total range (whiskers) and analysed using Mann-Whitney U-test (*p < 0.05, **p < 0.01, ***p < 0.005)
(See figure on next page.)
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predictive model with sufficient discrimination to delin-
eate an individual woman’s risk of adverse pregnancy 
outcome relating to advanced maternal age. This would 
allow older mothers to be offered more individualised 
care that considers both maternal and fetal wellbeing and 
reduces stillbirth rates whilst minimising unnecessary 
intervention.
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